<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305470</url>
  </required_header>
  <id_info>
    <org_study_id>NXDC-MEN-301</org_study_id>
    <nct_id>NCT04305470</nct_id>
  </id_info>
  <brief_title>Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma</brief_title>
  <acronym>MEN-301</acronym>
  <official_title>A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NX Development Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NX Development Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic&#xD;
      performance, and clinical usefulness of Gleolan for the real time detection and visualization&#xD;
      of meningiomas during tumor resection surgery. The study is planned to run for 15 months with&#xD;
      individual study participation lasting for approximately 2 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic&#xD;
      performance, and clinical usefulness of the imaging agent Gleolan™ (Aminolevulinic Acid&#xD;
      Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real time&#xD;
      detection and visualization of meningiomas during tumor resection surgery. ALA is a prodrug&#xD;
      that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX&#xD;
      (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in&#xD;
      tumor cells. Following excitation with blue light (BL) (λ = 375 - 440 nm), the PpIX, which&#xD;
      has accumulated selectively in tumor tissue, emits a red-violet light. This phenomenon allows&#xD;
      for the real-time visualization of tumor tissue during resection surgery.&#xD;
&#xD;
      Patients about to undergo resection for suspected meningioma [World Health Organization (WHO)&#xD;
      Grade I, II, III] will be screened and informed consent will be obtained prior to surgery and&#xD;
      prior to study participation. Eligible study participants will receive an oral solution of&#xD;
      Gleolan (20 mg/kg body weight) 3 hours, (target range 2-4 hours) prior to anesthesia, and&#xD;
      then undergo surgery for meningioma resection. During the surgery, the surgeon will use a&#xD;
      microscope equipped with WL and BL for visualization of Gleolan-induced PpIX fluorescence for&#xD;
      the selection of protocol-driven tissue locations and to assess fluorescence status.&#xD;
&#xD;
      Study participants will be evaluated within 48 hours post procedure, 2 weeks post procedure,&#xD;
      and 6 weeks post procedure for study safety assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 3, open-label, single arm study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants who have at least one indeterminate tissue or unexpected fluorescent End of Surgery (EOS) tissue where Gleolan-induced PpIX fluorescence status is consistent with histology.</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Per Protocol Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Predicted Value (PPV) of Gleolan-induced PpIX fluorescence of the single bulk tumor tissue obtained from each study participant</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Per Protocol Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of Gleolan-induced PpIX fluorescence among indeterminate tissue and unexpected fluorescent EOS tissue locations is at least 20% greater than the diagnostic accuracy of the surgeons' assessment.</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Biopsy Efficacy Analysis Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of Gleolan-induced PpIX fluorescence will be computed for indeterminate tissue biopsies, unexpected fluorescent EOS tissue biopsies.</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Biopsy Efficacy Analysis Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance between the Surgeon and Adjudication Panel assessment of white light (WL) visualization visualization to identify tissue as likely or unlikely to be meningioma among indeterminate tissues.</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Biopsy Efficacy Analysis Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance between the Surgeon and Adjudication Panel assessment of blue light (BL) visualization to identify fluorescence status of indeterminate tissues.</measure>
    <time_frame>Surgery (Day 1)</time_frame>
    <description>Biopsy Efficacy Analysis Population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, single-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)</intervention_name>
    <description>One time oral dose on day of surgery (20 mg/kg bodyweight)</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A pre-operative MRI within ≥ 90 days of study enrollment documenting a suspected&#xD;
             meningioma or suspected recurrence of a meningioma for which a complete meningioma&#xD;
             resection is indicated and has been planned.&#xD;
&#xD;
          2. Adult age ≥ 18 years.&#xD;
&#xD;
          3. Patient must have normal organ and bone marrow function and be appropriate surgical&#xD;
             candidates per site SOC.&#xD;
&#xD;
          4. Patient must have recording of each parameter as defined below:&#xD;
&#xD;
             Bilirubin Below upper limit of normal AST (SGOT) &lt; 2.5 X institutional upper limit of&#xD;
             normal ALT (SGPT) &lt; 2.5 X institutional upper limit of normal Creatinine Below upper&#xD;
             limit of normal OR Creatinine clearance &gt;60 mL/min/1.73 m2 for participants with&#xD;
             creatinine levels above institutional normal&#xD;
&#xD;
          5. The patient must demonstrate the ability to understand the informed consent document&#xD;
             and the willingness and ability to sign a written informed consent document. The study&#xD;
             consent documents will be prepared in English and German and Spanish. Translation for&#xD;
             non-English, non-German, or non-Spanish speaking participants will be provided as&#xD;
             appropriate by institution, as required.&#xD;
&#xD;
          6. WOCBP and men participating must agree to use highly effective forms of contraception,&#xD;
             and men must also agree not to donate sperm for the duration of treatment, and for at&#xD;
             least 42 days after the one time use of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic reactions attributed to compounds of similar chemical/biologic&#xD;
             composition to Gleolan.&#xD;
&#xD;
          2. Known or documented personal or family history of porphyria.&#xD;
&#xD;
          3. Uncontrolled concurrent illness, including but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia or psychiatric illness.&#xD;
&#xD;
          4. Patient has had a meningioma resection or radiation treatment within 90 days of&#xD;
             informed consent.&#xD;
&#xD;
          5. Social or medical situations that would limit compliance with study requirements (e.g.&#xD;
             ability to travel for follow-up or inability to obtain appropriate pre-op MRI (e.g.&#xD;
             cardiac pacemaker).&#xD;
&#xD;
          6. Women who are pregnant or plan to become pregnant during study participation.&#xD;
&#xD;
          7. Prior history of gastrointestinal perforation, diverticulitis, and or/peptic ulcer&#xD;
             disease.&#xD;
&#xD;
          8. Simultaneous participation in another clinical study or participation in another&#xD;
             clinical study in the 30 days directly preceding treatment or within 5 plasma&#xD;
             half-life of the preceding study drug, whatever is longer.&#xD;
&#xD;
          9. Simultaneous use of other potentially phototoxic substances (St. John's wort,&#xD;
             griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides,&#xD;
             quinolones and tetracyclines), and topical preparations containing ALA for 24 hours&#xD;
             during the perioperative period (see MOPS for detailed list).&#xD;
&#xD;
         10. Unwillingness by patient to sign consent or return for subsequent visits following&#xD;
             surgery.&#xD;
&#xD;
         11. Any condition that in the opinion of the Investigator would exclude the patient as a&#xD;
             viable candidate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Stummer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Bendok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Cox, MBA, CCRP</last_name>
    <phone>502-316-8981</phone>
    <email>acox@nxdevcorp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaylea Azealiix</last_name>
    <phone>737-837-5769</phone>
    <email>kazealiix@nxdevcorp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Turcotte</last_name>
      <email>turcotte.evelyn@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bernard Bendok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Schwartz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trey Garrett</last_name>
      <email>normanga@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel Zada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian Chen</last_name>
      <email>lillian.chen@stjoe.org</email>
    </contact>
    <contact_backup>
      <last_name>Joscelyn Green</last_name>
      <email>joscelyn.green@stjoe.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Anker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael McDermott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lokaitis</last_name>
      <phone>217-545-9737</phone>
      <email>blokaitis@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Cozzens, M.D., FAANS, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akeive Burrows</last_name>
      <email>ajburrows@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Bob Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Scarpace</last_name>
      <email>lscarpa1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa</last_name>
    </contact_backup>
    <investigator>
      <last_name>Adam Robin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiersten Sydnor</last_name>
      <email>kiersten.sydnor@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Van Gompel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathryn Lapierre</last_name>
      <email>cathryn.lapierre@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>John Golfinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donato Pacione, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodore Schwartz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Theodore Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania- Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Kerr, CCRP</last_name>
      <email>marie.kerr@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>John Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benita Valappil</last_name>
      <email>valappilb2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Zenonos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Stovall</last_name>
    </contact>
    <investigator>
      <last_name>Shaan Raza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Weinberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Widhalm, MD</last_name>
      <email>georg.widhalm@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Julia Freund</last_name>
      <email>julia.freund@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Georg Widhalm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Stummer, MD</last_name>
      <email>walter.stummer@ukmuenster.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALA</keyword>
  <keyword>fluorescence guided surgery</keyword>
  <keyword>Gleolan</keyword>
  <keyword>meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

